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In this issue of the Journal, Pappone et al. (1) and his
colleagues from Milan present the results of a non-
randomized prospective trial comparing ablation therapy to
medical therapy for management of atrial fibrillation (AF).
In this provocative study, these investigators analyze the
impact of a “curative ablative” approach to AF compared
with drug therapy for sinus rhythm (SR) maintenance. The
end points were mortality after a median follow-up of 900
days, quality of life measured with the 36-item short-form
general health survey (SF-36), morbidity (heart failure [HF]
and embolic events), and recurrent AF. Their results are
striking. A total of 1,171 patients were studied between
January 1998 and March 2001. The patients who had
ablation of AF had a lower mortality due exclusively to a
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lower rate of cardiovascular deaths, primarily HF, stroke,
and sudden death. In patients with a history of coronary
artery disease, ejection fraction 45%, and age 65 years,
survival was improved by 54%. Overall, survival for patients
who underwent ablation was identical to that for age- and
gender-matched persons in the Italian population.
With respect to the study’s other end points, there were
fewer episodes of HF and stroke in patients receiving
ablation therapy than in those receiving medical therapy.
Recurrence of AF was lower among patients receiving
ablation therapy (20% vs. 58%). Quality of life returned to
normal within six months in patients who underwent
ablation. Finally, for the first time, outcomes can be assessed
in a general population of patients with AF having a low
incidence both of recurrences of AF and of antiarrhythmic
drug use.
Historical perspective. Cox et al. (2) deserve credit for
pioneering an effective surgical approach for the treatment
of persistent AF. The maze procedure achieves a high
success rate for restoration of SR (90%) and presumably
works by modifying atrial substrate with suture lines placed
in both atria. In retrospect, it is likely that the placement of
many of the suture lines in or near the pulmonary veins and
in the posterior left atrium (LA) results in significant
reduction of the posterior LA available to sustain AF and
possibly also prevents conduction from triggering foci
within the pulmonary veins to the LA. The surgical lesions
created during the maze procedure formed electrical barriers
that prevented the maintenance of AF. The most widely
practiced catheter-based “curative” approach to the treat-
ment of AF was pioneered by Haissaguerre and his col-
leagues from Bordeaux in the late 1990s (3). This group
highlighted the importance of the pulmonary veins as
triggers for the initiation of paroxysmal AF (3,4). These
investigators showed that in patients with frequent atrial
ectopy and short bursts of AF, the site of initiation of AF
could be mapped to a location in or near the pulmonary
veins in over 90% of patients. Later, they were able to show
that empiric isolation of the pulmonary veins or the electri-
cal connections between the pulmonary veins and LA cured
many patients with paroxysmal AF, regardless of whether
they had frequent atrial ectopy.
Pappone et al. (1) have developed an approach to the
treatment of AF that combines aspects of both the maze and
pulmonary vein isolation approaches (i.e., ablation targeted
at both triggers and substrate modification). This technique
was initially described as “circumferential pulmonary vein
ablation” and has been applied successfully to patients with
both paroxysmal and chronic AF. In contrast, isolation of
the pulmonary veins near the os has shown disappointing
results for the treatment of chronic AF. The Pappone et al.
(1) approach is an anatomic-based strategy and often results
in pulmonary vein isolation or at least delay of PV activa-
tion, but it also significantly reduces posterior LA substrate
and probably extrapulmonary vein triggers too. To date,
follow-up studies of patients undergoing ablation with the
“Pappone approach” show that no patient has developed
pulmonary vein stenosis, one of the most feared complica-
tions of ablative approaches to AF.
What does this study mean in the post-AFFIRM
era? The recently published data from AFFIRM and
RACE suggest that patients enrolled in these trials did
equally well with respect to mortality and quality of life
whether they were maintained in SR with antiarrhythmic
drug therapy or left in AF with adequate heart rate (HR)
control (5,6). The failure of rhythm control to enhance
survival in these studies may be due to a true neutral effect
of the antiarrhythmic agents used, drug discontinuation, or
offsetting enhanced survival by maintaining SR with the
proarrhythmic effect of drugs. The conservative approach to
therapy of AF by these studies is in direct contrast to the
more aggressive interventional approach proposed by Pap-
pone et al. (1).
The study in this issue of the Journal raises a crucially
important question. If we can nonpharmacologically maintain
SR in a high percentage of patients with AF safely, survival
may be better than with either HR control or antiarrhyth-
mic drugs. This pivotal question must be answered in light
of the results of AFFIRM and RACE: Do we now have the
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ability to provide a better treatment for AF than antiar-
rhythmic drug therapy, potentially one that can also alleviate
the risk of long-term anticoagulation and stroke? In the
present trial, patients were not randomized to ablation or
medical therapy, and we do not know how the patients or
physicians made the decision to enroll individuals for drug
or ablation therapy. It is only through large-scale prospec-
tive randomized clinical trials that compare ablation therapy
for AF to antiarrhythmic drug therapy and to HR control
that we will get the answers clinicians need to best manage
these patients.
The current ablation therapy scenario. Most clinical cen-
ters performing radiofrequency ablation for the treatment of
AF perform pulmonary vein isolation using either lasso
catheters or baskets placed in the pulmonary veins (7).
Overall reported success rates for empiric pulmonary vein
isolation have been summarized to range between 47% and
83%, with 20% to 40% of patients taking antiarrhythmic
drugs and 10% to 30% of patients requiring a second
procedure (7–13). From a survey of centers with more than
1,000 patients who have undergone this procedure, tam-
ponade has been reported to occur in 1%, stroke in 1%, and
pulmonary vein stenosis in 1% to 3% (A. Natale, personal
communication, 2003). Unfortunately, results comparing
survival after pulmonary vein isolation with survival after
other therapies are not yet available. The approach advo-
cated by the Milan group has the advantage of avoiding
pulmonary vein stenosis by performing the ablation further
outside the pulmonary vein os. The low rate of tamponade
(0.7%) and stroke (0%) reported here is remarkable but
may, at least in part, be related to the need for only a
single transseptal puncture and less manipulation inside
and near the pulmonary vein os. The average procedure
time was only 3 h, which is quite acceptable to most
clinicians. Additionally, the evolution of the procedure
developed by Pappone as it is now practiced relies on the
use of 8-mm electrode catheters and higher radiofre-
quency energy to create larger and potentially continuous
LA lesions (14,15).
Future perspective. Pappone et al. (1) have now chal-
lenged us to re-evaluate the way we treat patients with AF.
Questions remain about how these findings apply to the
large population of patients with AF. The mean age of
patients in their study was 65 years, compared with mean
ages of 70 years in AFFIRM and 69 years in RACE.
Pappone routinely screened patients for asymptomatic re-
currences only at 1, 3, 6, 9, and 12 months. Symptomatic
arrhythmias were aggressively evaluated, but we know that
80% to 90% of AF episodes may be asymptomatic (16).
Future trials should make a concerted effort to evaluate
patients for asymptomatic AF. The majority of patients
with adverse events in this study (72%) had AF at the time
of the event. All four cases of peripheral embolism, 89% of
the transient ischemic attacks, and 79% of the ischemic
strokes occurred in patients with AF. These findings argue
strongly for the realization that AF is not a benign disease
in many patients.
In the present study, anticoagulation with warfarin was
stopped after SR had been maintained for three months. As
a result, about 50% of the patients who had thromboembolic
complications were receiving inadequate or no anticoagulant
therapy. In light of AFFIRM, the number of embolic events
in patients receiving antiarrhythmic agents would have been
likely to decrease if anticoagulation had been maintained
throughout the study period. The issue of when and if all
patients with ablation can safely discontinue warfarin is not
answered by this study. The overall average risk of major or
potentially fatal bleeding events while being treated with
warfarin is 0.7% per year (17). Finally, the rationale for the
choice of individual antiarrhythmic drugs was not discussed
in the manuscript, and the patients in this trial were taking
a large number of different agents. The dosing and moni-
toring of these patients receiving antiarrhythmic agents is
not well detailed.
Pappone et al. (1) are to be congratulated on the logistics
of this careful long-term follow-up of patient outcomes after
circumferential pulmonary vein ablation. The number of
patients studied, the low risk of complications, and the high
incidence of SR are impressive. Importantly, many of these
patients had significant structural heart disease, and the
patient population studied was fairly diverse. Because of
these findings, interventional electrophysiologists will need
to closely study the methods and results of AF described in
the Journal. Reproducibility of these findings by other
interventional electrophysiologists will also be an important
early goal (18). Future randomized trials of therapy for AF
must now seriously consider inclusion of an ablation arm.
Both the work of Pappone et al. (1) and the work of
Haissaguerre et al. (3,4) have begun a new chapter in the
therapy for AF. It will be the work of clinical trialists to help
us decide how these ablation therapies will find a place
among our therapies for patients with AF.
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